Skip to content
approvedImmune & Inflammation

Thymogen

Also known as: Glu-Trp, EW dipeptide, Glutamyl-Tryptophan

Thymogen is a synthetic dipeptide (L-Glutamyl-L-Tryptophan) developed by Vladimir Khavinson as the minimal active fragment of thymalin's immune-modulating activity. Approved in Russia as an immunostimulant, it restores T-cell function and corrects immune imbalances. As a dipeptide bioregulator, it represents Khavinson's principle that tissue-specific regulation can be achieved with peptides as short as two amino acids, making it one of the simplest bioactive peptides known.

3 cited references·4 researched benefits

Quick Answer

Thymogen (Glu-Trp) is a synthetic dipeptide immune bioregulator approved in Russia that represents the minimal active unit of thymic immune-modulating activity. This two-amino-acid peptide restores T-lymphocyte function and corrects immune imbalances in immunocompromised states. It demonstrates the Khavinson bioregulation principle that even dipeptides can regulate tissue-specific gene expression. Available in Russia as intranasal spray and injectable forms for immunodeficiency treatment.

Key Facts

Mechanism
Thymogen (Glu-Trp) is proposed to interact directly with DNA in immune cells, binding specific promoter regions to upregulate genes involved in T-lymphocyte differentiation and cytokine production. Despite being only two amino acids, the specific Glu-Trp sequence reportedly shows selective affinity for regulatory DNA sequences in immune-related genes. It enhances T-helper cell function, normalizes CD4/CD8 ratios, increases production of thymic hormones, and modulates cytokine balance toward appropriate immune responses. The tryptophan component may additionally serve as a serotonin and melatonin precursor.
Research Status
approved
Half-Life
~30 minutes
Molecular Formula
C₁₆H₁₉N₃O₆
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • T-cell restoration — normalizes T-lymphocyte subsets and CD4/CD8 ratios in immunocompromised patientsmoderate
  • Simple and stable — two-amino-acid structure is metabolically stable and easily synthesizedstrong
  • Infection prevention — reduced incidence of acute respiratory infections in clinical studiesmoderate
  • Intranasal availability — approved as nasal spray in Russia for convenient non-invasive administrationmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intranasal spray25–100 mcgDaily for 3–10 daysAvailable in Russia as 0.01% nasal spray. Standard course: daily administration for 3–10 days, repeated every 3–6 months for immune support.
Intramuscular injection100 mcgDaily for 3–10 daysInjectable form used in more severe immunodeficiency states.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nasal irritation — mild discomfort with intranasal administrationcommon
  • Generally well-tolerated — very few adverse effects reported in Russian clinical literaturerare

Frequently Asked Questions

How can a two-amino-acid peptide have biological activity?
The Khavinson bioregulation theory proposes that short peptides interact with complementary DNA sequences to regulate gene expression. The Glu-Trp dipeptide is proposed to have selective affinity for specific regulatory DNA elements in immune cell genes. While this mechanism remains controversial in Western science, there are precedents for short peptide bioactivity: carnosine (Ala-His) has antioxidant properties, aspartame (Asp-Phe methyl ester) activates taste receptors, and many dipeptides survive intestinal absorption intact. The key question is specificity — can a dipeptide truly target tissue-specific gene regulation?
What is the clinical evidence for thymogen?
Russian clinical studies (primarily published in Russian-language journals) report benefits in secondary immunodeficiency, post-surgical immune recovery, acute respiratory infection prevention in elderly populations, and as adjunctive therapy in chronic infections. These studies generally show improvements in T-cell counts, CD4/CD8 ratios, and clinical outcomes. The evidence base has limitations by Western standards: many studies lack double-blinding, randomization, or placebo controls. No large-scale international clinical trials have been conducted.
How does thymogen compare to thymosin alpha-1?
Thymosin alpha-1 (Tα1) is a 28-amino-acid peptide with extensive international clinical data, while thymogen is a 2-amino-acid peptide with primarily Russian clinical data. Tα1 has well-characterized mechanisms (TLR activation, dendritic cell maturation) and is approved in multiple countries for hepatitis B. Thymogen is simpler, cheaper to produce, and has a proposed DNA-regulatory mechanism that is less well-validated. For immune enhancement, Tα1 has stronger evidence; thymogen's advantage is simplicity and cost.

References

  1. 1
    Thymogen: immunomodulatory properties and clinical applications(2006)
  2. 2
    Short peptides as bioregulators: the role of dipeptides in immune function(2014)PubMed ↗
  3. 3
    Peptide bioregulators: a new class of geroprotectors(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19